© 2025 - 2026
The Life Science Feed. All rights reserved.
A digital publication from Grá & Mawi Media Co.
Fixed-Duration BCL-2 Combo Offers Time Off Treatment in 1L CLL
A novel fixed-duration combination therapy with a BCL-2 inhibitor as backbone provides treatment-free intervals for patients with first-line CLL.
